<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861103</url>
  </required_header>
  <id_info>
    <org_study_id>HS# 2019-5544</org_study_id>
    <nct_id>NCT04861103</nct_id>
  </id_info>
  <brief_title>Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)</brief_title>
  <official_title>Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnancy is associated with a increased risk of developing blood clots. There is nearly a 5&#xD;
      times greater risk of developing a blood clot in pregnancy. Lovenox is a medication that&#xD;
      helps to prevent the body from developing clots. It is safe to use in pregnancy. Previous&#xD;
      studies have demonstrated that despite recommendation of Lovenox, to prevent blood clots, the&#xD;
      majority of patient's (70 to 90%) did not receive adequate levels of Lovenox at times&#xD;
      throughout the day, which likely increases the risk of developing clots. The increase in&#xD;
      blood volume and increase in kidney function that occurs in pregnancy may contribute to the&#xD;
      inadequate levels. Currently the recommendation for pregnant and nonpregnant patients&#xD;
      requiring Lovenox, is to calculate the daily dose of Lovenox and split the dose, giving half&#xD;
      in the morning and the other half in the evening. This research study proposes that due to&#xD;
      changes in the body during pregnancy that the daily Lovenox dosing be split into three times&#xD;
      a day to achieve more consistent levels of Lovenox than twice a day in pregnant women.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Factor Xa levels</measure>
    <time_frame>4 hours after injection</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pregnancy, High Risk</condition>
  <condition>Anticoagulants</condition>
  <arm_group>
    <arm_group_label>Factor Xa levels in pregnant women with therapeutic Lovenox divided into three times a day dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic Lovenox dosing split into three times a day dosing for 5 day. Xa levels a measured.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovenox</intervention_name>
    <description>Three times a day dosing and measuring Xa peak and trough levels</description>
    <arm_group_label>Factor Xa levels in pregnant women with therapeutic Lovenox divided into three times a day dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Nulliparous or multiparous women with single intrauterine pregnancies who require&#xD;
        therapeutic low molecular weight heparin during their pregnancy.&#xD;
&#xD;
        Participants must be age 18 or older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Women with multiples. Women less than age 18 History of Heparin Induced Thrombocytopenia&#xD;
        (HIT) Allergy to enoxaparin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afshan Hameed</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lizette Spears</last_name>
    <phone>714.456.5694</phone>
    <email>lspiers@hs.uci.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lizette Spears</last_name>
      <phone>714-456-5694</phone>
      <email>lspiers@hs.uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Phuong Linh L Huynh</last_name>
      <phone>714.456.6155</phone>
      <email>plhuynh@hs.uci.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Afshan B. Hameed, M.D.</investigator_full_name>
    <investigator_title>Maternal Fetal Medicine Physician</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

